POSTER: Development of Multiplex xMAP Technology-Based Assays for Simultaneous Detection of Soluble Checkpoint Molecules Involved in Anti-Cancer Immune Response

Speaker

Abstract

To ensure the immune system’s balance between the recognition of non-self and the prevention of autoimmunity, the activity of immune cells needs to be strictly controlled. During the process of cancerogenesis, tumor cells try to resist immune responses and work to suppress the cycle of cancer immunity through multiple mechanisms involving regulatory proteins. These proteins—referred to as immune checkpoints—can affect immunoregulatory pathways by either boosting (co-stimulatory) or restricting (co-inhibitory) the immune response. For the majority of these checkpoint markers, soluble isoforms or shed variants that function as immune adjuvants or decoy receptors, have been identified. To date, cancer therapies that use antibodies targeted to the proteins within these immune checkpoint pathways have proven effective. It is also hypothesized that the measurement of the circulating concentration of the soluble forms of the immune checkpoint proteins could potentially correlate with the clinical efficacy of corresponding checkpoint modulator drugs.

To test this hypothesis, we developed two comprehensive multiplexing panels (using Luminex® xMAP® technology) that are specifically designed to detect soluble checkpoint molecules involved in T cell and NK cell regulation. The panels allow the simultaneous detection of immune stimulatory and inhibitory factors, allowing a more holistic picture of the molecular players in cancer immunity. Preliminary results using the Invitrogen™ Immuno-Oncology Checkpoint 14-Plex Human ProcartaPlex™ Panel 1 (Cat. No. EPX14A-15803-901) and the Invitrogen™ Immuno-Oncology Checkpoint 14-Plex Human ProcartaPlex™ Panel 2 (Cat. No. EPX140-15815-901) demonstrate that there are different expression patterns for each that are dependent on both disease state and patient treatment. More in-depth analysis of these soluble biomarkers will hopefully shed more light on the biology of the immune checkpoint pathways and provide a possible tool for monitoring response to therapeutic treatment.

Learning Objectives:

  • Investigate the advantage of using soluble checkpoint molecules as potential markers for the response to chemotherapy
  • Develop immunoassays for new immune regulating targets

Show Resources
You May Also Like
APR 01, 2021 8:00 AM PDT
C.E. CREDITS
APR 01, 2021 8:00 AM PDT
Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
APR 21, 2021 10:00 AM PDT
C.E. CREDITS
APR 21, 2021 10:00 AM PDT
Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
JUL 15, 2021 9:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
JUL 15, 2021 9:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Date: July 15, 2021 Time: 9:00am (PDT), 12:00pm (EDT) The Pisces workflow robust, easy-to-use, end-to-end multi-omics solution for highly multiplexed targeted Spatial RNA analysis. VeranomeB...
FEB 24, 2021 10:00 AM PST
C.E. CREDITS
FEB 24, 2021 10:00 AM PST
DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
JUN 03, 2021 12:00 PM CST
JUN 03, 2021 12:00 PM CST
DATE: June 3, 2021 TIME: 12:00pm SGT This webinar is a virtual event that focuses on utilizing the Gibco CTS Rotea System for Cell and Gene Therapy...
JUN 08, 2021 9:00 AM PDT
JUN 08, 2021 9:00 AM PDT
Date: June 8, 2021 Time: 9:00am PDT Reducing the spread of highly infectious and deadly diseases within the population, vaccine development is crucial in saving millions of lives each year....

POSTER: Development of Multiplex xMAP Technology-Based Assays for Simultaneous Detection of Soluble Checkpoint Molecules Involved in Anti-Cancer Immune Response


Specialty

Research And Development

Cancer

Immunology

Biomarkers

Earth Science

University

Immuno-Oncology

Cancer Diagnostics

Antibodies

Research

Infectious Disease

Cancer Research

Assay Development

Health

Geography

Asia50%

Europe50%

Registration Source

Website Visitors100%

Job Title

Facility/Department Manager50%

Medical Laboratory Technician50%

Organization

Manufacturer - Other50%

Life Science Company50%


Show Resources
Loading Comments...
Show Resources
Attendees
  • See more